Sanofi reported first‑quarter 2026 results that surpassed analyst expectations, with adjusted earnings per share of $1.10 versus a consensus estimate of $1.06, and revenue of $12.307 billion against an estimate of $11.990 billion. The $0.04 earnings beat and $0.317 billion revenue beat reflect stronger-than‑anticipated demand across the company’s core immunology portfolio.
The growth was driven primarily by the continued success of Dupixent, whose sales rose 30.8% year‑over‑year to €4.17 billion, and by robust performance in the newly launched pharma products, including Altuviiio, Ayvakit, and Sarclisa, which together contributed €1.2 billion in sales. Vaccine sales also grew 2.1% to €1.3 billion, helped by the inclusion of Heplisav‑B. Cost controls and operational efficiencies kept operating margins healthy, with business operating income up 10.9% at constant exchange rates to €2.97 billion and an operating margin of 28.2%.
Compared with the same quarter last year, Sanofi’s revenue increased 13.6% to €10.51 billion, and business earnings per share grew 14.0% to €1.88. The company’s U.S. sales reached €5.289 billion, up 26.2% at constant exchange rates, underscoring the strength of its North American market presence.
Sanofi’s management reaffirmed its 2026 outlook, maintaining guidance for high‑single‑digit sales growth at constant exchange rates and for business earnings per share to grow slightly faster than sales. The company reiterated its confidence in the pipeline and its ability to sustain profitability amid upcoming patent expirations for key products.
Interim CEO Olivier Charmeil highlighted the company’s disciplined cost management and the momentum of its product launches, stating, “We had a strong start to 2026 with double‑digit sales and business EPS growth. Sales increased by 13.6%, supported by Pharma launches and recent acquisitions. Dupixent sales were above the €4 billion quarterly mark again and grew by 30.8%. Business EPS was up by 14.0%, reflecting a measured growth of 7.0% in total operating expenses.” He also noted the company’s confidence in its guidance and the upcoming transition to new CEO Belén Garijo.
Investors responded positively to the results, citing the earnings and revenue beats, the robust performance of Dupixent and new product launches, and the company’s reaffirmed guidance as evidence of strong execution and a solid outlook for the remainder of the year.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.